Advances with vaccination against Neisseria meningitidis

Tropical Medicine and International Health

Volumn 17, Issue 12, 2012, Pages 1478-1491

  Borrow, Ray ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Conjugate; Meningococcus; Polysaccharide; Vaccine

Indexed keywords

ADHESIN; AFRIVAC; ANTIBODY; HEPARIN BINDING ANTIGEN; LP2086; MENINGOCOCCUS VACCINE; NEISSERIAL ADHESIN A; POLYSACCHARIDE VACCINE; PORIN A; RECOMBINANT PROTEIN; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANTIBODY; BACTERIUM; DISEASE CONTROL; DRUG DEVELOPMENT; HEALTH IMPACT; MEDICINE; POLYSACCHARIDE; PUBLIC HEALTH; VACCINATION;

ARTICLE; CLINICAL EFFECTIVENESS; DRUG SAFETY; HEALTH CARE POLICY; HEALTH SURVEY; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; MENINGOCOCCOSIS; NASOPHARYNX; NEISSERIA MENINGITIDIS; NONHUMAN; SINGLE DRUG DOSE; VACCINATION;

CONJUGADA; CONJUGATE; CONJUGUÉ; MÉNINGOCOQUE; MENINGOCOCCUS; MENINGOCOCO; POLISACÁRIDO; POLYSACCHARIDE; VACCIN; VACCINE; VACUNA;

BACTERIAL PROTEINS; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; RECOMBINANT PROTEINS; VACCINES, CONJUGATE;

SUB-SAHARAN AFRICA;

NEISSERIA MENINGITIDIS;

EID: 84869864015     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2012.03085.x     Document Type: Article

References (151)

1. African meningococcal carriage consortium (2011). MenAfriCar. http://www.menafricar.org/ Last accessed 12th October 2011.
2. Ala'Aldeen DA, Davies HA & Borriello SP (1994) Vaccine potential of meningococcal FrpB: studies on surface exposure and functional attributes of common epitopes. Vaccine12, 535-541.
3. Andrews N, Borrow R & Miller E (2003) Validation of serological correlate of protection for meningococcal C conjugate vaccine using efficacy estimates from post-licensure surveillance in England. Clinical and Diagnostic Laboratory Immunology10, 780-786.
4. Arora A (2009) World vaccine congress. Expert Review of Vaccines8, 135-138.
5. Auckland C, Gray S, Borrow R et al. (2006) Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the UK. Journal of Infectious Diseases194, 1745-1752.
6. Bai X, Findlow J & Borrow R (2011) Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opinion in Biological Therapy11, 969-985.
7. Baker MG, Martin DR, Kieft CE & Lennon D (2001) A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000. Journal of Paediatric Child Health37, S13-S19.
8. Bambini S, Muzzi A, Olcen P, Rappuoli R, Pizza M & Comanducci M (2009) Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine27, 2794-2803.
9. Beernink PT, Leipus A & Granoff DM (2006) Rapid genetic grouping of factor h-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate. Clinical and Vaccine Immunology13, 758-763.
10. Beernink PT, Welsch JA, Harrison LH, Leipus A, Kaplan SL & Granoff DM (2007) Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. Journal of Infectious Diseases195, 1472-1479.
11. Beernink PT, Shaughnessy J, Braga EM et al. (2011) A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. Journal of Immunology186, 3606-3614.
12. Biolchi A, Kleinschmidt A, Boccadifuoco G et al. (2010) Evaluation of the contribution of protein antigen NHBA to bactericidal antibody responses in sera from human vaccines enrolled in clinical trials. The 17th International Pathogenic Neisseria Conference, Banff, Canada. Abstract number P188. Page 171.
13. Bjune G, Hoiby EA, Gronnesby JK et al. (1991) Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet338, 1093-1096.
14. Boisier P, Nicolas P, Djibo S et al. (2007) Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clinical Infectious Diseases44, 657-663.
15. Borrow R (2009) Meningococcal disease and prevention at the Hajj. Travel Medicine and Infectious Disease7, 219-225.
16. Borrow R, Fox AJ, Richmond PC et al. (2000) Induction of immunological memory in UK infants by a meningococcal A/C conjugate vaccine. Epidemiology and Infection124, 427-432.
17. Borrow R, Andrews N, Goldblatt D & Miller E (2001a) Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: a re-evaluation of correlates of protection. Infection and Immunity69, 1568-1573.
18. Borrow R, Southern J, Andrews N et al. (2001b) Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naïve controls. Vaccine19, 3043-3050.
19. Borrow R, Goldblatt D, Andrews N, Richmond P, Southern J & Miller E (2001c) Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. Journal of Infectious Diseases184, 377-380.
20. Borrow R, Carlone GM, Rosenstein N et al. (2006) Neisseria meningitidis group B correlates of protection and assay standardization - International Meeting Report Emory University, Atlanta Georgia United States, 16-17 March 2005. Vaccine24, 5093-5107.
21. Borrow R, Andrews N, Findlow H et al. (2010) Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine at 12 to 15months of age in healthy UK infants primed with two doses of one of three monovalent meningococcal serogroup C vaccines. Clinical and Vaccine Immunology17, 154-159.
22. Boslego J, Garcia J, Cruz C et al. (1995) Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine13, 821-829.
23. Bröker M, Cooper B, Detora LM & Stoddard JJ (2011) Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive disease. Infection and Drug Resistance4, 137-147.
24. Burrage M, Robinson A, Borrow R et al. (2002) Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infection and Immunity70, 4946-4954.
25. Campbell H, Andrews N, Borrow R, Trotter C & Miller E (2010) Updated post-licensure surveillance of meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlate of protection and modelling predictions of the duration of herd immunity. Clinical and Vaccine Immunology17, 840-847.
26. Capecchi B, Adu-Bobie J, Di Marcello F et al. (2005) Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Molecular Microbiology55, 687-698.
27. Cartwright KAV, Richmond P, Morris R et al. (1999) Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 outer membrane proteins. Vaccine17, 2612-2619.
28. Caugant DA (2008) Genetics and evolution of Neisseria meningitidis: importance for the epidemiology of meningococcal disease. Infection, Genetics and Evolution8, 558-565.
29. Centers for Disease Control and Prevention (CDC) (2011a) Updated recommendations for use of meningococcal conjugate vaccines - Advisory board on Immunization Practices (ACIP), 2010. Morbidity and Mortality Weekly Report60, 72-76.
30. Centers for Disease Control and Prevention (CDC) (2011b) Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23months at increased risk for invasive meningococcal disease. Morbidity and Mortality Weekly Report60, 1391-1392.
31. Chief Medical Officer, Chief Nursing Officer and the Chief Pharmacist (2006). Important changes to the childhood immunisation programme. PL/CMO/2006/1, PL/CNO/2006/1, PL/CPHO/2006/1.
32. Comanducci M, Bambini S, Brunelli B et al. (2002) NadA, a novel vaccine candidate of Neisseria meningitidis. Journal of Experimental Medicine195, 1445-1454.
33. Comanducci M, Bambini S, Caugant DA et al. (2004) NadA diversity and carriage in Neisseria meningitidis. Infection and Immunity72, 4217-4223.
34. de Greeff SC, de Melker HE, Spanjaard L, Schouls LM & van Derende A (2006) Protection from routine vaccination at the age of 14months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatric Infectious Disease Journal25, 79-80.
35. de Kleijn ED, de Groot R, Labadie J et al. (2000) Immunogenicity and safety of a hexavalent meningococcal outer-membrane- vesicle vaccine in children of 2-3 and 7-8years of age. Vaccine18, 1456-1466.
36. de Moraes JC, Perkins BA, Camargo MCC et al. (1992) Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet340, 1074-1078.
37. de Wals P, Deceuninck G, Lefebvre B, Boulianne N & de Serres G (2011) Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada. Pediatric Infectious Disease Journal30, 566-569.
38. Department of Health (2007) Immunisation against infectious disease -'The Green Book'- 2006 updated edition. Chapter 22 Meningococcal. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_125942.pdf Last accessed 21st October 2011.
39. Donnelly J, Medini D, Boccadifuoco G et al. (2010) Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proceedings of the National Academy of Sciences of the United States of America107, 19490-19495.
40. Donnelly J, Medini D, Giuliani M et al. (2011) Estimating the potential strain coverage in Europe of a multicomponent vaccine targeting serogroup B meningococci. The European Meningococcal Disease Society (EMGM) 11th meeting, Ljubljana, Slovenia, page 17.
41. EU-IBIS (2007). Conjugate meningococcal serogroup C vaccination programmes in the EU, as at October 2007. http://www.hpa-bioinformatics.org.uk/euibis/meningo/vacc_sched_meningo.htm.
42. Fairley CK, Begg N, Borrow R, Fox AJ, Jones DM & Cartwright K (1996) Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. Journal of Infectious Diseases174, 1360-1363.
43. Figueroa J, Andreoni J & Densen P (1993) Complement deficiency states and meningococcal disease. Immunologic Research12, 295-311.
44. Fijen CA, Kuijper EJ, te Bulte MT, Daha MR & Dankert J (1999) Assessment of complement deficiency in patients with meningococcal disease in The Netherlands. Clinical Infectious Diseases28, 98-105.
45. Findlow J, Borrow R, Snape MD et al. (2010) Multicentre, open-label, randomised phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clinical Infectious Diseases51, 1127-1137.
46. Findlow H, Sow S, Borrow R et al. (2011) Meningococcal group C and W135 immunological hyporesponsiveness in African toddlers. Clinical and Vaccine Immunology18, 1492-1496.
47. Findlow H, Borrow R, Andrews N et al. (2012) Immunogenicity of a single dose of meningococcal group C conjugate vaccine, at 3months of age in healthy infants in the United Kingdom. Paediac Infectious Disease Journal31, 616-622.
48. Finne J, Leinonen M & Makela PH (1983) Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet2, 355-357.
49. Fletcher LD, Bernfield L, Barniak V et al. (2004) Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infection and Immunity72, 2088-2100.
50. Frasch CE, Zollinger WD & Poolman JT (1985) Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Reviews of Infectious Diseases7, 504-510.
51. Galloway Y, Stehr-Green P, McNicholas A & O'Hallahan J (2009) Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5years. International Journal of Epidemiology38, 413-418.
52. Giuliani MM, Adu-Bobie J, Comanducci M et al. (2006) A universal vaccine for serogroup B meningococcus. Proceedings of the National Academy of Sciences of the United States of America103, 10834-10839.
53. Giuliani MM, Biolchi A, Serruto D et al. (2010) Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine28, 5023-5030.
54. Gold R, Lepow ML, Goldschneider I, Draper TL & Gotschlich EC (1975) Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. The Journal of Clinical Investigation56, 1536-1547.
55. Gold R, Lepow ML, Goldschneider I, Draper TF & Gotshlich EC (1979) Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. Journal of Infectious Diseases140, 690-697.
56. Goldschneider I, Gotschlich EC & Artenstein MS (1969) Human immunity to the meningococcus. I. The role of humoral antibodies. Journal of Experimental Medicine129, 1307-1326.
57. Gorringe AR, Borrow R, Fox AJ & Robinson A (1995) Human antibody response to meningococcal transferrin binding proteins: evidence for vaccine potential. Vaccine13, 1207-1212.
58. Gossger N, Snape MD, Yu LM et al. (2012) Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without infant vaccinations according to different immunization schedules: a randomized controlled trial. The Journal of the American Medical Association307, 573-582.
59. Granoff DM, Gupta RK, Belshe RB & Anderson EL (1998) Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. Journal of Infectious Diseases178, 870-874.
60. Greenwood B (1999) Manson Lecture. Meningococcal meningitis in Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene93, 341-353.
61. Harrison LH, Trotter CL & Ramsay ME (2009) Global epidemiology of meningococcal disease. Vaccine27(Suppl 2), B51-B63.
62. Health Protection Agency (2009) Laboratory confirmed cases of all invasive meningococcal disease by age and calendar year, England and Wales 1998 to 2010 (provisional). Accessed 30th September 2011, at http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1234510034636?p=1201094595391.
63. Hedberg ST, Törös B, Fredlund H, Olcén P & Mölling P (2011) Genetic characterisation of the emerging invasive Neisseria meningitidis serogroup Y in Sweden, 2000 to 2010. Eurosurveillance16(23), pii: 19885.
64. Hung MC, Salim O, Williams JN, Heckels JE & Christodoulides M (2011) The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate. Infection and Immunity79, 3784-3791.
65. Imrey PB, Jackson LA, Ludwinski PH et al. (1996) Outbreak of serogroup C meningococcal disease associated with campus bar patronage. American Journal of Epidemiology143, 624-630.
66. Jiang HQ, Hoiseth SK, Harris SL et al. (2010) Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine28, 6086-6093.
67. Jodar L, Cartwright K & Feavers IM (2000) Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines. Biologicals28, 193-197.
68. Jodar L, Feavers IM, Salisbury D & Granoff DM (2002) Development of vaccines against meningococcal disease. The Lancet359, 1499-1508.
69. Jokhdar H, Borrow R, Sultan A et al. (2004) Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clinical and Diagnostic Laboratory Immunology11, 83-88.
70. Keiser PB, Gibbs BT, Coster TS et al. (2010) A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA. Vaccine28, 6970-6976.
71. Keiser PB, Biggs-Cicatelli S, Moran EE et al. (2011) A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine29, 1413-1420.
72. Keyserling H, Papa T, Koranyi K et al. (2005) Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Archives of Pediatric and Adolescent Medicine159, 907-913.
73. Knuf M, Kieninger-Baum D, Habermehl P et al. (2010) A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine28, 744-753.
74. Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U et al. (2011) An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine29, 4264-4273.
75. Kristiansen PA, Diomandé F, Wei SC et al. (2011) Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine. Clinical and Vaccine Immunology18, 435-443.
76. Kshirsagar N, Mur N, Thatte U et al. (2007) Safety and immunogenicity of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine25S, A101-A107.
77. Ladhani SN, Lucidarme J, Newbold LS et al. (2012) Increase in invasive meningococcal capsular group Y disease in England and Wales. Emerging Infectious Diseases18, 63-70.
78. LaForce FM & Okwo-Bele JM (2011) Eliminating epidemic group A meningococcal meningitis in Africa through a new vaccine. Health Affairs (Millwood)30, 1049-1057.
79. LaForce FM, Konde K, Viviani S & Préziosi MP (2007) The meningitis vaccine project. Vaccine25(Suppl 1), A97-A100.
80. Larrauri A, Cano R, Garcia M & Mateo S (2005) Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine23, 4097-4100.
81. Litt DJ, Savino S, Beddek A et al. (2004) Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. Journal of Infectious Diseases190, 1488-1497.
82. Lucidarme J, Comanducci M, Findlow J et al. (2009) Characterisation of fHbp, nhba (gna2132), nadA, porA, Sequence Type and the genomic presence of IS1301 in group B meningococcal ST269 clonal complex case isolates from England and Wales. Journal of Clinical Microbiology47, 3577-3585.
83. Lucidarme J, Comanducci M, Findlow J et al. (2010) Characterisation of fHbp, nhba (gna2132), nadA, porA and Sequence Type in group B meningococcal case isolates collected in England and Wales during January 2008, and potential coverage of an investigational group B meningococcal vaccine. Clinical and Vaccine Immunology17, 919-929.
84. MacDonald NE, Halperin SA, Law BJ, Forrest B, Danzig LE & Granoff DM (1998) Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. The Journal of the American Medical Association280, 1685-1689.
85. MacLennan J, Obaro S, Deeks J et al. (2001) Immunologic memory 5years after meningococcal A/C conjugate vaccination in infancy. Journal of Infectious Diseases183, 97-104.
86. MacNeil J, Cohn AC, Mair R et al. (2010) Interim analysis of the effectiveness of quadrivalent meningococcal conjugate vaccine (MenACWY-D): a matched case-control study. 17th International Pathogenic Neisseria Conference, Banff, Canada, page 42.
87. Maiden MC & Feavers IM (1994) Meningococcal typing. Journal of Medical Microbiology40, 157-158.
88. Maiden MC, Bygraves JA, Feil E et al. (1998) Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proceedings of the National Academy of Sciences of the United States of America95, 3140-3145.
89. Maiden MC, Russell J, Suker J & Feavers IM (1999) Neisseria meningitidis subtype nomenclature. Clinical and Diagnostic Laboratory Immunology6, 771-772.
90. Maiden MC, Stuart JM & for the Meningococcal Carriage Group (2002) Carriage of serogroup C meningococci 1year after meningococcal C conjugate polysaccharide vaccine. The Lancet359, 1829-1831.
91. th Meeting, Ljubljana, Slovenia, Abstract P046. Pages 130-131.
92. Martin P, van de Ven T, Mouchel N, Jeffries AC, Hood DW & Moxon ER (2003) Experimentally revised repertoire of putative contingency loci in Neisseria meningitidis strain MC58: evidence for a novel mechanism of phase variation. Molecular Microbiology50, 245-257.
93. Masignani V, Comanducci M, Giuliani MM et al. (2003) Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. Journal of Experimental Medicine197, 789-799.
94. Maslanka SE, Gheesling LL, LiButti DE et al. (1997) Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clinical and Diagnostic Laboratory Immunology4, 156-167.
95. McNeil LK, Zlotnick GW, Camposano E et al. (2011) Development of a meningococcal antigen surface expression (MEASURE) assay for the phenotypic characterization of fHBP expression by Neisseria meningitidis. The European Meningococcal Disease Society (EMGM) 11th Meeting, Ljubljana, Slovenia, Abstract number O09. Pages 19-20.
96. Meningitis Vaccine Project (2011). http://www.meningvax.org/ Last accessed 12th October 2011.
97. Metruccio MM, Pigozzi E & Roncarati D et al. (2009) A novel phase variation mechanism in the meningococcus driven by a ligand-responsive repressor and differential spacing of distal promoter elements. PLoS Pathogen5, e1000710.
98. Miller E, Salisbury D & Ramsay M (2001) Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine20, S58-S67.
99. Miller JM, Mesaros N, van der Wielen M & Baine Y (2011) Conjugate meningococcal vaccines development: GSK Biologicals Experience. Advances in Preventative Medicine2011, 846756.
100. Molesworth AM, Thomson MC, Connor SJ et al. (2002) Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene96, 242-249.
101. Morrow HW, Slaten DD, Reingold AL, Werner SB & Fenstersheib MD (1990) Risk factors associated with a school-related outbreak of serogroup C meningococcal disease. Pediatric Infectious Disease Journal9, 394-398.
102. Mueller JE, Borrow R & Gessner BD (2006) Meningococcal serogroup W135 in the African Meningitis Belt: epidemiology, Immunity and Vaccines. Expert Review of Vaccines5, 319-336.
103. Murphy E, Andrew L, Lee K-L et al. (2009) Sequence diversity of vaccine candidate LP2086 (Factor H Binding Protein) in epidemiologically relevant strains of serogroup B Neisseria meningitidis. Journal of Infectious Diseases200, 379-389.
104. Neisseria Factor H binding protein sequence typing (2011). http://pubmlst.org/neisseria/fHbp/ Last accessed 20th October 2011.
105. Neisseria PorA typing (2011). http://pubmlst.org/neisseria/PorA/ Last accessed 18th October 2011.
106. Nissen M, Marshall H, Richmond P et al. (2008) A randomized, placebo-controlled, double-blind, Phase 1 trial of ascending doses of meningococcal group B rLP2086 vaccine. Presented at: 26th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Graz, Austria, Abstract number 128.
107. O'Hallahan J, McNicholas A, Galloway Y, O'Leary E & Roseveare C (2009) Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease. New Zealand Medical Journal122, 48-59.
108. Pajon R, Beernink PT, Harrison LH & Granoff DM (2010) Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine28, 2122-2129.
109. Peeters CC, Rümke HC, Sundermann LC et al. (1996) Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine14, 1009-1015.
110. Perrett KP, Snape MD, Ford KJ et al. (2009) Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatric Infectious Disease Journal28, 186-193.
111. Pinto VB, Moran EE, Cruz F et al. (2011) An experimental outer membrane vesicle vaccine from N. meningitides serogroup B strains that induces serum bactericidal activity to multiple serogroups. Vaccine29, 7752-7758.
112. Pizza M, Scarlato V, Masignani V et al. (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science287, 1816-1820.
113. Poolman JT, van der Ley PA & Tommassen J (1995) Surface structures of meningococci. In: Meningococcal Disease (ed Cartwright K) John Wiley & Sons, Chichester, pp. 21-34.
114. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB & Miller E (2003) Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ326, 365-366.
115. Rappuoli R (2000) Reverse vaccinology. Current Opinions in Microbiology3, 445-450.
116. Richmond P, Borrow R, Miller E et al. (1999) Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. Journal of Infectious Diseases179, 1569-1572.
117. Richmond P, Kaczmarski E, Borrow R et al. (2000) Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. Journal of Infectious Diseases181, 761-764.
118. Richmond P, Borrow R, Findlow J et al. (2001a) Evaluation of de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming and bactericidal activity against O-acetylated and de-O-acetylated serogroup C strains. Infection and Immunity69, 2378-2382.
119. Richmond P, Borrow R, Goldblatt D et al. (2001b) Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. Journal of Infectious Diseases183, 160-163.
120. Richmond P, Marshall HS, Nissen MD et al. (2008) A randomized, observed-blinded, active control, Phase 1 trial of meningococcal serogroup B rLP2086 vaccine in healthy children and adolescent aged 8 to 14years. Presented at: International Pathogenic Neisseria Conference. Rotterdam, the Netherlands, Abstract number P212. Pages 270-271.
121. Rosenstein NE, Perkins BA, Stephens DS et al. (1999) The changing epidemiology of meningococcal disease in the United States, 1992-1996. Journal of Infectious Diseases180, 1894-1901.
122. Santolaya ME, O'Ryan ML, Valenzuela MT et al. (2012) Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet379, 617-624.
123. Saukkonen K, Leinonen M, Abdillahi H & Poolman JT (1989) Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine7, 325-328.
124. Schneider MC, Prosser BE, Caesar JJ et al. (2009) Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature458, 890-893.
125. Serruto D, Spadafina T, Ciucchi L et al. (2010) Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proceedings of the National Academy of Sciences of the United States of America107, 3770-3775.
126. Sierra GV, Campa HC, Varcacel NM et al. (1991) Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. National Institute of Public Health Annals14, 195-207.
127. Snape MD, Kelly DF, Lewis S et al. (2008a) Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ336, 1487-1491.
128. Snape MD, Perrett KP, Ford KJ et al. (2008b) Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. The Journal of the American Medical Association299, 173-184.
129. Snape MD, Dawson T, Oster P et al. (2010) Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life. A randomized comparative trial. Pediatric Infectious Disease Journal29, e71-e79.
130. Song J, Minetti CA, Blake MS & Colombini M (1999) Meningococcal PorA/C1, a channel that combines high conductance and high selectivity. Biophysical Journal76, 804-813.
131. Southern J, Deane S, Ashton L et al. (2004) Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clinical and Diagnostic Laboratory Immunology11, 1100-1104.
132. Sow S, Okoko BJ, Diallo A et al. (2011) Immunogenicity, safety, and induction of immune memory of a new meningococcal group A conjugate vaccine in 1 to 29year-old West Africans. New England Journal of Medicine364, 2293-2304.
133. Stephens DS (2007) Conquering the meningococcus. FEMS Microbiology Reviews31, 3-14.
134. Stephens DS, Greenwood B & Brandtzaeg P (2007) Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. The Lancet369, 2196-2210.
135. Stork M, Bos MP, Jongerius I et al. (2010) An outer membrane receptor of Neisseria meningitidis involved in zinc acquisition with vaccine potential. PLoS Pathogens6, e1000969.
136. Tan LKK, Carlone GM & Borrow R (2010) Advances in the development of vaccines against Neisseria meningitidis. New England Journal of Medicine362, 1511-1520.
137. Tappero JW, Lagos R, Ballesteros AM et al. (1999) Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. The Journal of the American Medical Association281, 1520-1527.
138. Tommassen J, Verme P, Struyve M, Benz R & Poolman JT (1990) Isolation of Neisseria meningitidis mutants deficient in class 1 (PorA) and class 3 (PorB) outer membrane proteins. Infection and Immunity58, 1355-1359.
139. Toneatto D, Ismaili S, Ypma E, Vienken K, Oster P & Dull P (2011) The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Human Vaccines7, 646-653.
140. Trotter CL & Ramsay ME (2007) Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiology Reviews31, 101-107.
141. Tsai CM, Frasch CE & Mocca LF (1981) Five structural classes of major outer membrane proteins in Neisseria meningitidis. Journal of Bacteriology146, 69-78.
142. van den Dobbelsteen GP, van Dijken HH, Pillai S & van Alphen L (2007) Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine25, 2491-2496.
143. van der Ley PA, Heckels JE, Virji M, Hoogerhout P & Poolman JT (1990) Topology of outer membrane porins in pathogenic Neisseria spp. Infection and Immunity59, 2963-2971.
144. van der Ley P, van der Biezen J & Poolman JT (1995) Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine13, 401-407.
145. Vesikari T, Karvonen A, Bianco V, Van der Wielen M & Miller J (2011) Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: an open, randomized controlled trial. Vaccine29, 4274-4284.
146. Vieusseux G (1806) Mémoire sur la maladie qui a regné a Genêve au printemps de 1805. Journal de Médecine, de Chirurgie et de Pharmacologie (Bruxelles) Med Chir Pharm11, 163-182.
147. Wong S, Lennon D, Jackson C et al. (2007) New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24months. Pediatric Infectious Diseases Journal26, 345-350.
148. World Health Organization, Global Alert and Response (GAR) (2011) Meningococcal disease in Chad. Accessed 30th September 2011, at http://www.who.int/csr/don/2011_03_08/en/index.html.
149. Wyle FA, Artenstein MS, Brandt BL et al. (1972) Immunologic response of man to group B meningococcal polysaccharide vaccines. Journal of Infectious Diseases126, 514-521.
150. Zollinger WD, Moran EE & Schmiel DH (2009) Characterization of an antibody depletion assay for analysis of bactericidal antibody specificity. Clinical and Vaccine Immunology16, 1789-1795.
151. Zollinger WD, Donets MA, Schmiel DH et al. (2010) Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine28, 5057-5067.